DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma
- 2 December 2022
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (3) , 334-336
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K23 HL141445)
- U.S. Department of Health & Human Services | National Institutes of Health (U10HL069294)
This publication has 10 references indexed in Scilit:
- Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Frontiers in Oncology, 2022
- Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myelomaAmerican Journal of Hematology, 2022
- Associations between indicators of socioeconomic position and DNA methylation: a scoping reviewClinical Epigenetics, 2021
- Discovery of Candidate DNA Methylation Cancer Driver GenesCancer Discovery, 2021
- Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adultsBiomarker Research, 2019
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialJournal of Clinical Oncology, 2019
- Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple MyelomaTransplantation and Cellular Therapy, 2018
- Prospective changes in global DNA methylation and cancer incidence and mortalityBritish Journal of Cancer, 2016
- Global Measures of Peripheral Blood-Derived DNA Methylation as a Risk Factor in the Development of Mature B-Cell NeoplasmsEpigenomics, 2015
- DNA Methylation Dynamics in Blood after Hematopoietic Cell TransplantPLOS ONE, 2013